
Solventum trades at a discount with raised 2026 EPS guidance and potential spin-off plans.
Solventum is currently trading at a significant discount compared to its medical technology peers, with a forward price-to-earnings ratio of about 13 times and low EV/EBITDA multiples. The company’s management is actively optimizing its portfolio, in...





